Analyst Ratings for CRISPR Therapeutics (CRSP)
CRSP Rating Summary
CRSP Price Target Summary
- Highest: $110.00 (Piper Sandler)
- Lowest: $6.00 (Baird)
- Average: $68.07
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$68.07 (+38.2%)
* Over Last 12-Mos
Rating Score: 5.4 / 10
Percentile Rank: 57%
Avg. $ Target:
$68.07 (+38.2%)
* Over Last 12-Mos
Rating Score: 5.4 / 10
Percentile Rank: 57%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/14/2026 | UBS | N/A | New Coverage | Neutral (N/A) |
52.00 (N/A) |
50.10 (49.25) |
-1.7% | Details |
| 6/11/2026 | Morgan Stanley | Maxwell Skor | New Coverage | Equalweight (N/A) |
60.00 (N/A) |
51.48 (49.25) |
-4.33% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
